|
Delayed
Berne S.E.
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | - |
| Market Cap | 5.2B 4.57B 4.31B 3.93B 7.35B 499B 7.41B 51.72B 20.04B 254B 19.52B 19.09B 826B | P/E 2026 * |
40x | P/E 2027 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3.33B 2.93B 2.76B 2.52B 4.71B 319B 4.74B 33.1B 12.83B 163B 12.49B 12.22B 529B | EV / Sales 2026 * |
2.64x | EV / Sales 2027 * | 2.22x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PTC Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 54 | 22/03/2023 |
Pierre Gravier
DFI | Director of Finance/CFO | 41 | 13/07/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/10/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 01/11/2004 | |
Allan Jacobson
CHM | Chairman | 80 | 31/03/1998 |
David Southwell
BRD | Director/Board Member | 65 | 01/12/2005 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 5.2B | |
| +0.20% | +2.56% | +59.32% | +114.68% | 1,053B | |
| +0.19% | +0.17% | +53.19% | +68.65% | 652B | |
| -0.33% | +0.42% | +20.51% | +73.58% | 468B | |
| -0.52% | +1.29% | +41.73% | +44.82% | 351B | |
| +0.64% | +3.91% | +22.04% | +29.30% | 273B | |
| +0.84% | 0.00% | +14.09% | +11.67% | 254B | |
| -0.05% | +6.91% | +45.42% | +51.68% | 220B | |
| -0.75% | -0.80% | +31.69% | +99.56% | 186B | |
| +0.25% | -9.73% | -29.62% | -60.11% | 170B | |
| Average | +0.08% | +0.30% | +28.71% | +48.20% | 403.04B | |
| Weighted average by Cap. | +0.16% | +1.00% | +39.10% | +67.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.26B 1.11B 1.04B 952M 1.78B 121B 1.79B 12.52B 4.85B 61.45B 4.72B 4.62B 200B | 1.38B 1.21B 1.14B 1.04B 1.95B 132B 1.96B 13.7B 5.31B 67.27B 5.17B 5.06B 219B |
| Net income | 145M 128M 121M 110M 206M 13.96B 207M 1.45B 561M 7.1B 546M 534M 23.12B | 231M 204M 192M 175M 327M 22.22B 330M 2.3B 892M 11.31B 869M 850M 36.8B |
| Net Debt | -1.87B -1.65B -1.55B -1.42B -2.65B -180B -2.67B -18.62B -7.21B -91.41B -7.03B -6.87B -297B | -2.15B -1.89B -1.78B -1.62B -3.04B -206B -3.06B -21.35B -8.27B -105B -8.06B -7.88B -341B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTCT Stock
- P91 Stock
Select your edition
All financial news and data tailored to specific country editions
